2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

ASH 2025 Review: Updates in Frontline & R/R DLBCL

University of Colorado Division of Hematology

M. Kamdar

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Insights: POLARIX 5yr Update - Pola-R-CHP vs. R-CHOP in 1L …

2024 ASH Annual Meeting Insights Hub

G. Salles

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Golcadomide + R-CHOP in High-Risk, Untreated Aggressive B-Cell Lymph…

Moffitt Cancer Center

Y. Zhang, B. Shah, J. Chavez, M. Jain, S. Gaballa

2025 Updates in DLBCL

Total Health

F. Hagemeister

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Tandem 2025 Insights: Real-World Evidence Study Assessing Efficacy a…

Insights from 2025 Tandem Annual Meeting

G. Shouse

DLBCL: Treatment Options for Transplant-Ineligible Patients

Amit Mehta

ASH 2024 Treatment Updates in Lymphoma: Practice Changing and Promis…

UChicago Medicine

A. Rojek

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

Current Approaches and Ongoing Trials in Frontline DLBCL Treatment

Grzegorz Nowakowski